Our review article (1) focused exclusively on patients with primary headache—such as migraine, cluster headache, or chronic tension headache—who overused analgesics and migraine medication. Very few studies exist on the epidemiology and clinical presentation of headache due to overuse of analgesics in secondary headache. No controlled therapeutic studies exist for this patient population. For this reason we did not include this group of patients in our review.
On behalf of the authors
Prof. Dr. med. Hans-Christoph Diener
Seniorprofessur für Klinische Neurowissenschaften
Universitätsklinik für Neurologie und
Westdeutsches Kopfschmerzzentrum, Essen
Conflict of interest statement
Prof Hans-Christoph Diener has received honoraria for the planning or execution of clinical trials or participation in them, for serving on advisory boards, or for delivering lectures, from the following companies: Addex Pharma, Alder, Allergan, Almirall, Amgen, AstraZeneca, Autonomic Technology, Bayer Vital, Berlin Chemie, Böhringer Ingelheim, Bristol-Myers Squibb, Chordate, CoLucid, Coherex, Electrocore, EndoPharma, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Johnson & Jonson, Labrys Biologicals, Lilly, La Roche, 3M Medica, MAP, Medtronic, Menarini, Minster, MSD, Neuroscore, Novartis, Novo-Nordisk, Pierre Fabre, Pfizer, Reckitt Benckiser, Sanofi, Schaper und Brümmer, Schering, St. Jude Medical, Teva, and Weber & Weber.
He has received financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, Electrocore, GSK, Janssen-Cilag, MSD, and Pfizer.
|1.||Diener HC, Holle D, Dresler T, Gaul C: Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int 2018; 115: 365–70 VOLLTEXT|